研究者詳細 - 菅　博人

論文 - 菅　博人

分割表示 65 件中 1 - 20 件目／全件表示 >>

Blood-brain barrier water exchange and paramagnetic susceptibility alterations during anti-amyloid therapy: preliminary MRI findings. Open Access

Uchida Y, Kano Y, Kan H, Sakurai K, Morita H, Akagawa Y, Matsukawa N, Oishi K

The journal of prevention of Alzheimer's disease.. 頁： 100256 2025年6月

Uncrossed Cerebellar Diaschisis in Hemimegalencephaly: Evaluated by FDG-PET and Diffusion Tensor Tractography.

Kagaya R, Maki H, Matsuda H, Kan H, Kimura Y, Shigemoto Y, Imokawa T, Iijima K, Iwasaki M, Nakagawa E, Sato N

International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience 85 巻 ( 3 ) 頁： e70022 2025年5月

MR Imaging Indices for Brain Interstitial Fluid Dynamics and the Effects of Orexin Antagonists on Sleep.

Taoka T, Iwamoto K, Miyata S, Ito R, Nakamichi R, Nakane T, Okada I, Ichikawa K, Kan H, Kamagata K, Kikuta J, Aoki S, Fujimoto A, Kogo Y, Ichinose N, Naganawa S, Ozaki N

Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine advpub 巻 ( 0 ) 2025年2月

Water/fat separate reconstruction for body quantitative susceptibility mapping in MRI.

Kan H, Nakashima M, Tsuchiya T, Yamada M, Hiwatashi A

Radiological physics and technology 2025年1月

Deep-learning assessment of hippocampal magnetic susceptibility in Alzheimer's disease.

Shibata H, Uchida Y, Kan H, Sakurai K, Madokoro Y, Iwano S, Maurya SK, Muñoz-González Á, Ardakani I, Yamada K, Matsukawa N

Journal of Alzheimer's disease : JAD 頁： 13872877241300278 2024年11月

Quantitative susceptibility mapping analyses of white matter in Parkinson's disease using susceptibility separation technique.

Nakashima M, Kan H, Kawai T, Matsumoto K, Kawaguchi T, Uchida Y, Matsukawa N, Hiwatashi A

Parkinsonism & related disorders 128 巻頁： 107135 2024年9月

Association of medullary reticular formation ventral part with spasticity in mice suffering from photothrombotic stroke.

Isumi S, Futamura D, Hanasaki T, Sako Y, Miyata S, Kan H, Suzuki Y, Hasegawa N, Mushiake H, Kametaka S, Uchiyama Y, Osanai M, Lee-Hotta S

NeuroImage 頁： 120791 2024年8月

Quantitative Susceptibility Mapping for Susceptibility Source Separation with Adaptive Relaxometric Constant Estimation (QSM-ARCS) from Solely Gradient-Echo Data.

Kan H, Uchida Y, Kawaguchi S, Kasai H, Hiwatashi A, Ueki Y

NeuroImage 頁： 120676 2024年6月

Alterations in subcortical magnetic susceptibility and disease-specific relationship with brain volume in major depressive disorder and schizophrenia.

Shibukawa S, Kan H, Honda S, Wada M, Tarumi R, Tsugawa S, Tobari Y, Maikusa N, Mimura M, Uchida H, Nakamura Y, Nakajima S, Noda Y, Koike S

Translational psychiatry 14 巻 ( 1 ) 頁： 164 2024年3月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Translational Psychiatry

Quantitative susceptibility mapping is a magnetic resonance imaging technique that measures brain tissues’ magnetic susceptibility, including iron deposition and myelination. This study examines the relationship between subcortical volume and magnetic susceptibility and determines specific differences in these measures among patients with major depressive disorder (MDD), patients with schizophrenia, and healthy controls (HCs). This was a cross-sectional study. Sex- and age- matched patients with MDD (n = 49), patients with schizophrenia (n = 24), and HCs (n = 50) were included. Magnetic resonance imaging was conducted using quantitative susceptibility mapping and T1-weighted imaging to measure subcortical susceptibility and volume. The acquired brain measurements were compared among groups using analyses of variance and post hoc comparisons. Finally, a general linear model examined the susceptibility–volume relationship. Significant group-level differences were found in the magnetic susceptibility of the nucleus accumbens and amygdala (p = 0.045). Post-hoc analyses indicated that the magnetic susceptibility of the nucleus accumbens and amygdala for the MDD group was significantly higher than that for the HC group (p = 0.0054, p = 0.0065, respectively). However, no significant differences in subcortical volume were found between the groups. The general linear model indicated a significant interaction between group and volume for the nucleus accumbens in MDD group but not schizophrenia or HC groups. This study showed susceptibility alterations in the nucleus accumbens and amygdala in MDD patients. A significant relationship was observed between subcortical susceptibility and volume in the MDD group’s nucleus accumbens, which indicated abnormalities in myelination and the dopaminergic system related to iron deposition.

DOI： 10.1038/s41398-024-02862-7

Scopus

PubMed

Anisotropy of the R1/T2* value dependent on white matter fiber orientation with respect to the B0 field.

Kawaguchi S, Kan H, Uchida Y, Kasai H, Hiwatashi A, Ueki Y

Magnetic resonance imaging 2024年2月

Longitudinal Changes in Iron and Myelination Within Ischemic Lesions Associate With Neurological Outcomes: A Pilot Study.

Uchida Y, Kan H, Kano Y, Onda K, Sakurai K, Takada K, Ueki Y, Matsukawa N, Hillis AE, Oishi K

Stroke 2024年1月

Brain Abnormalities in Becker Muscular Dystrophy: Evaluation by Voxel-Based DTI and Morphometric Analysis.

Maki H, Mori-Yoshimura M, Matsuda H, Hashimoto Y, Ota M, Kimura Y, Shigemoto Y, Ishihara N, Kan H, Chiba E, Arizono E, Yoshida S, Takahashi Y, Sato N

AJNR. American journal of neuroradiology 2023年11月

Blood-Brain Barrier Function Associates with Brain Iron Dynamics along Developmental Trajectory: A Combined Quantitative Magnetic Resonance Imaging Study during Childhood

Uchida, Y; Kan, H; Furukawa, G; Onda, K; Sakurai, K; Takada, K; Matsukawa, N; Oishi, K

ANNALS OF NEUROLOGY 94 巻頁： S209 - S210 2023年9月

Relationship between brain iron dynamics and blood-brain barrier function during childhood: a quantitative magnetic resonance imaging study.

Uchida Y, Kan H, Furukawa G, Onda K, Sakurai K, Takada K, Matsukawa N, Oishi K

Fluids and barriers of the CNS 20 巻 ( 1 ) 頁： 60 2023年8月

Three-compartment spectral diffusion analysis for breast cancer magnetic resonance imaging.

Ogawa M, Kan H, Urano M, Kawai T, Nakajima H, Murai K, Miyaji H, Toyama T, Hiwatashi A

Magnetic resonance imaging 2023年5月

Voxel-Based and Surface-Based Morphometry Analysis in Patients with Pathologically Confirmed Argyrophilic Grain Disease and Alzheimer's Disease.

Sakurai K, Kaneda D, Morimoto S, Uchida Y, Inui S, Kimura Y, Kan H, Kato T, Ito K, Hashizume Y

Journal of Alzheimer's disease : JAD 2023年3月

Contributions of blood-brain barrier imaging to neurovascular unit pathophysiology of Alzheimer's disease and related dementias.

Uchida Y, Kan H, Sakurai K, Oishi K, Matsukawa N

Frontiers in aging neuroscience 15 巻頁： 1111448 2023年

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Frontiers in Aging Neuroscience

The blood–brain barrier (BBB) plays important roles in the maintenance of brain homeostasis. Its main role includes three kinds of functions: (1) to protect the central nervous system from blood-borne toxins and pathogens; (2) to regulate the exchange of substances between the brain parenchyma and capillaries; and (3) to clear metabolic waste and other neurotoxic compounds from the central nervous system into meningeal lymphatics and systemic circulation. Physiologically, the BBB belongs to the glymphatic system and the intramural periarterial drainage pathway, both of which are involved in clearing interstitial solutes such as β-amyloid proteins. Thus, the BBB is believed to contribute to preventing the onset and progression for Alzheimer’s disease. Measurements of BBB function are essential toward a better understanding of Alzheimer’s pathophysiology to establish novel imaging biomarkers and open new avenues of interventions for Alzheimer’s disease and related dementias. The visualization techniques for capillary, cerebrospinal, and interstitial fluid dynamics around the neurovascular unit in living human brains have been enthusiastically developed. The purpose of this review is to summarize recent BBB imaging developments using advanced magnetic resonance imaging technologies in relation to Alzheimer’s disease and related dementias. First, we give an overview of the relationship between Alzheimer’s pathophysiology and BBB dysfunction. Second, we provide a brief description about the principles of non-contrast agent-based and contrast agent-based BBB imaging methodologies. Third, we summarize previous studies that have reported the findings of each BBB imaging method in individuals with the Alzheimer’s disease continuum. Fourth, we introduce a wide range of Alzheimer’s pathophysiology in relation to BBB imaging technologies to advance our understanding of the fluid dynamics around the BBB in both clinical and preclinical settings. Finally, we discuss the challenges of BBB imaging techniques and suggest future directions toward clinically useful imaging biomarkers for Alzheimer’s disease and related dementias.

DOI： 10.3389/fnagi.2023.1111448

Web of Science

Scopus

PubMed

Assessing white matter microstructural changes in idiopathic normal pressure hydrocephalus using voxel-based R2* relaxometry analysis.

Kano Y, Uchida Y, Kan H, Sakurai K, Kobayashi S, Seko K, Mizutani K, Usami T, Takada K, Matsukawa N

Frontiers in neurology 14 巻頁： 1251230 2023年

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Frontiers in Neurology

Background: R2* relaxometry and quantitative susceptibility mapping can be combined to distinguish between microstructural changes and iron deposition in white matter. Here, we aimed to explore microstructural changes in the white matter associated with clinical presentations such as cognitive impairment in patients with idiopathic normal-pressure hydrocephalus (iNPH) using R2* relaxometry analysis in combination with quantitative susceptibility mapping. Methods: We evaluated 16 patients clinically diagnosed with possible or probable iNPH and 18 matched healthy controls (HC) who were chosen based on similarity in age and sex. R2* and quantitative susceptibility mapping were compared using voxel-wise and atlas-based one-way analysis of covariance (ANCOVA). Finally, partial correlation analyses were performed to assess the relationship between R2* and clinical presentations. Results: R2* was lower in some white matter regions, including the bilateral superior longitudinal fascicle and sagittal stratum, in the iNPH group compared to the HC group. The voxel-based quantitative susceptibility mapping results did not differ between the groups. The atlas-based group comparisons yielded negative mean susceptibility values in almost all brain regions, indicating no clear paramagnetic iron deposition in the white matter of any subject. R2* and cognitive performance scores between the left superior longitudinal fasciculus (SLF) and right sagittal stratum (SS) were positively correlated. In addition to that, R2* and gait disturbance scores between left SS were negatively correlated. Conclusion: Our analysis highlights the microstructural changes without iron deposition in the SLF and SS, and their association with cognitive impairment and gait disturbance in patients with iNPH.

DOI： 10.3389/fneur.2023.1251230

Web of Science

Scopus

PubMed

Noncontrast time-resolved pulmonary magnetic resonance angiography with consecutive beam saturation pulse and variable flip angles using three-dimensional fast spin echo: A preliminary study. 国際誌

Kan H, Mizuno K, Takizawa M, Shimohira M, Kawai T, Aoki T, Tsubokura S, Kasai H

Magnetic resonance imaging 94 巻頁： 80 - 88 2022年12月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：Magnetic Resonance Imaging

To develop and validate a novel noncontrast time-resolved magnetic resonance angiography (NC TR-MRA) using consecutive beam pulses with variable flip angles for visualizing hemodynamics in the pulmonary artery, we performed phantom and volunteer studies and applied the novel NC TR-MRA to a 51-year-old woman with pulmonary arteriovenous malformation (PAVM).The novel NC TR-MRA sequence utilized consecutive multiple-beam saturation pulses with variable flip angles considering venous blood T1 relaxation to alter the visualized blood signal length. The flowing blood signal length is suppressed according to the number of beam saturation pulses. NC TR-MRA in each flow phase was assessed by subtracting the images with and without beam saturation pulses. In the flow phantom study, three flow velocities were used to simulate physiological pulmonary arterial blood flow. Signal profiles along the flow direction were evaluated in each flow phase. In the volunteer study, five healthy volunteers were recruited, and NC TR-MRA was applied to evaluate relationships between the flow-saturated time and signal enhancement rates. Four regions of interest (ROIs) were determined on the proximal and distal portions of the right basal artery. A patient with PAVM was included to validate whether a PAVM lesion could be visualized using NC TR-MRA. The visualized flow signal lengths extended proportionally with the number of beam saturation pulses in the steady-flow phantom at all velocities. In the volunteer study, NC TR-MRA images showed signal enhancement from the proximal to distal portions of the right basal artery with increase in the flow-saturated time. Signal enhancement rates in all ROIs were significantly positively correlated with the flow-saturated time (p < 0.001 in all ROIs). Further, the lesion and its hemodynamics could be explicitly visualized in the patient with PAVM. Hence, NC TR-MRA using beam saturation pulse can visualize the hemodynamics of the pulmonary artery and may be useful for diagnosing and following patients with PAVM.

DOI： 10.1016/j.mri.2022.09.001

Web of Science

Scopus

PubMed

Memantine for the patients with mild cognitive impairment in Parkinson’s disease: a pharmacological fMRI study

Kawashima S., Shimizu Y., Horiba M., Ueki Y., Akanabe R., Kan H., Kasai H., Kunitomo H., Tanaka S., Toyota T., Kawashima S., Mizuno M., Okita K., Matsukawa N.

BMC Neurology 22 巻 ( 1 ) 2022年12月

記述言語：英語掲載種別：研究論文（学術雑誌）出版者・発行元：BMC Neurology

Background: Mild cognitive impairment in Parkinson’s disease (PD-MCI) is associated with an increased risk of cognitive decline. PD-MCI is characterized by impairments in executive function and visuospatial recognition. The visuospatial n-back test is useful for assessing both domains. The 0-back test reflects visuospatial recognition, while the 1-back and 2-back tests reflect working memory. Cholinesterase inhibitors are effective in the treatment of PD-MCI and dementia in PD (PDD). Although some studies have reported the efficacy of memantine for PDD, the therapeutic efficacy of memantine in patients with PD-MCI remains uncertain. Methods: This study aimed to investigate the effects of memantine on brain function in patients with PD-MCI, using a randomized double-blinded crossover protocol and functional MRI (fMRI). Ten patients who completed 16 weeks of follow-up were included. They were randomly assigned to either the memantine or placebo. Patients in the memantine group received 5 mg/day of memantine in the first week. The memantine dose was increased by 5 mg/day per week, until a final dose of 20 mg/day. Patients in the placebo group received the placebo following the same regimen as memantine. After the intervention, they underwent a 4 weeks washout period. Following the crossover protocol, a second intervention was conducted after the washout period. In each intervention, fMRI and neuropsychological tests were performed at the maximum dose period. Comparing the memantine and placebo groups, we investigated difference in the brain regions using the visuospatial n-back test. Results: There were no significant regions enhanced by memantine comparing with placebo at any load of n-back tests. In contrast, exploring regions reduced by memantine, we found significant reduction of activations within right lingual gyrus and left superior frontal gyrus in comparison between 2-back and 0-back test. A number of correct answers of the 2-back test and time to complete Trail Making Test-A were worse during memantine intervention. Conclusions: Memantine did not improve visuospatial working memory of the patients with PD-MCI. Treatment for PD should be planned carefully considering the impact on cognitive function. Further study is needed to establish new therapeutic strategy. Trial registration: UMIN000046104. Retrospectively registered. First registration date: 28 Sept 2017.

DOI： 10.1186/s12883-022-02699-x

Scopus

　前のページ - 次のページ　

<菅 博人>

論文 - 菅 博人

<菅　博人>

論文 - 菅　博人